Shanghai Fosun Pharmaceutical Obtains Authorization for New Indication of Hans-Zhong Drug

MT Newswires Live12-04

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with pemetrexed and carboplatin.

The new indication is for the "first-line treatment of epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer," according to a Tuesday filing with the Shanghai bourse.

The approval will further enhance the market competitiveness of the drug and bring more treatment options to patients with non-squamous non-small cell lung cancer in China, the company said.

Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2488718442?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-04 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488718442","market":"us","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical Obtains Authorization for New Indication of Hans-Zhong Drug","media":"MT Newswires Live","content":"<html><body><p> Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with pemetrexed and carboplatin.</p><p>The new indication is for the \"first-line treatment of epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer,\" according to a Tuesday filing with the Shanghai bourse.</p><p>The approval will further enhance the market competitiveness of the drug and bring more treatment options to patients with non-squamous non-small cell lung cancer in China, the company said.</p><p>Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical Obtains Authorization for New Indication of Hans-Zhong Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical Obtains Authorization for New Indication of Hans-Zhong Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-04 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488718442","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488718442","pubTimestamp":1733283273,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical  obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with pemetrexed and carboplatin.The new indication is for the \"first-line treatment of epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer,\" according to a Tuesday filing with the Shanghai bourse.The approval will further enhance the market competitiveness of the drug and bring more treatment options to patients with non-squamous non-small cell lung cancer in China, the company said.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","02196":"复星医药","BK0175":"白马股","BK0239":"医药制造","BK0096":"民营医院","BK0188":"融资融券","BK0028":"国家队","00656":"复星国际","BK1191":"制药","BK0187":"一线龙头","BK0183":"MSCI概念","BK0196":"行业龙头","BK0060":"抗癌","BK0012":"证金概念","BK1515":"抗疫概念"},"translate_title":"上海复星医药获得汉斯中药物新适应症授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1,"02196":0.9},"content_text":"Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) obtained authorization from the National Medical Products Administration for a new indication for its Hans-Zhong drug in combination with pemetrexed and carboplatin.The new indication is for the \"first-line treatment of epidermal growth factor receptor gene mutation-negative and anaplastic lymphoma kinase-negative unresectable locally advanced or metastatic non-squamous non-small cell lung cancer,\" according to a Tuesday filing with the Shanghai bourse.The approval will further enhance the market competitiveness of the drug and bring more treatment options to patients with non-squamous non-small cell lung cancer in China, the company said.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488718442"}